may result from ischemia/reperfusion injury, in certain embodiments. In certain embodiments, the RKD results from diabetes or hypertension. The RKD may result from an autoimmune disease. The RKD may be further defined as chronic RKD, or acute RKD.

In certain methods of treating renal/kidney disease (RKD) in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure, the subject has undergone or is undergoing dialysis. In certain embodiments, the subject has undergone or is a candidate to undergo kidney transplant. The subject may be a primate. The primate may be a human. The subject in this or any other method may be, for example, a cow, horse, dog, cat, pig, mouse, rat or guinea pig.

Also contemplated by the present disclosure is a method for improving glomerular filtration rate or creatinine clearance in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure.

In some embodiments, the pharmaceutical composition is administered in a single dose per day. In other embodiments, the pharmaceutical composition is administered in more than one dose per day. In some embodiments, the pharmaceutical composition is administered in a pharmaceutically effective amount.

In some embodiments, the active ingredient is administered in a dose from about 1 mg/kg to about 2000 mg/kg. In other embodiments, the dose is from about 3 mg/kg to about 100 mg/kg. In other embodiments, the dose is about 3, 10, 30, or 100 mg/kg.

In other embodiments, the pharmaceutical composition is administered topically. In some embodiments, the topical administration is administered to the skin. In other embodiments, the topical administration is administered to the eye.

In other embodiments, the pharmaceutical composition is administered orally. In other embodiments, the pharmaceutical composition is administered intraocularly.

In another aspect of the invention, there is provided the use of a therapeutically effective amount of the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating or preventing a condition associated with inflammation or oxidative stress in a patient in need thereof.

Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those

26. The pharmaceutical composition of claim 22, wherein the amount of the active ingredient is about 3% by weight.

27. ~~A method of treating or preventing a condition associated with inflammation or oxidative stress in a patient in need thereof, comprising administering to the patient~~ Use of a therapeutically effective amount of the pharmaceutical composition according to any one of claims 9 to 26 in the manufacture of a medicament for treating or preventing a condition associated with inflammation or oxidative stress in a patient in need thereof.

28. The ~~method~~ use of claim 27, wherein the condition is associated with inflammation.

29. The ~~method~~ use of claim 27, wherein the condition is associated with oxidative stress.

30. The ~~method~~ use according to any one of claims 27-29, wherein the condition is a skin disease or disorder, sepsis, dermatitis, osteoarthritis, cancer, inflammation, an autoimmune disease, inflammatory bowel disease, a complication from localized or total-body exposure to ionizing radiation, mucositis, acute or chronic organ failure, liver disease, pancreatitis, an eye disorder, a lung disease, or diabetes.

31. The ~~method~~ use of claim 30, wherein the condition is a skin disease or disorder.

32. The ~~method~~ use of claim 31, wherein the skin disease or disorder is dermatitis, a thermal or chemical burn, a chronic wound, acne, alopecia, other disorders of the hair follicle, epidermolysis bullosa, sunburn, complications of sunburn, a disorder of skin pigmentation, an aging-related skin condition, a post-surgical wound, a scar from a skin injury or burn, psoriasis, a dermatological manifestation of an autoimmune disease or a graft-versus host disease, skin cancer, a disorder involving hyperproliferation of skin cells.

33. The ~~method~~ use of claim 32, wherein the skin disease or disorder is dermatitis.

34. The ~~method~~ use of claim 33, wherein the dermatitis is allergic dermatitis, atopic dermatitis, dermatitis due to chemical exposure, or radiation-induced dermatitis.

35. The ~~method~~ use of claim 33, wherein the skin disease or disorder is a chronic wound.

36. The ~~method~~ use of claim 35, wherein the chronic wound is a diabetic ulcer, a pressure sore, or a venous ulcer.

37. The ~~method~~ use of claim 32, wherein the skin disease or disorder is alopecia.

38. The ~~method~~ use of claim 37, wherein the alopecia is selected from baldness and drug-induced alopecia.

39. The ~~method~~ use of claim 32, wherein the skin disease or disorder is a disorder of skin pigmentation.

40. The ~~method~~ use of claim 39, wherein the disorder of skin pigmentation is vitiligo.

41. The ~~method~~ use of claim 32, wherein the skin disease or disorder is a disorder involving hyperproliferation of skin cells.

42. The ~~method~~ use of claim 41, wherein the disorder involving hyperproliferation of skin cells is hyperkeratosis.

43. The ~~method~~ use of claim 30, wherein the condition is an autoimmune disease.

44. The ~~method~~ use of claim 43, wherein the condition is rheumatoid arthritis, lupus, Crohn's disease, or psoriasis.

45. The ~~method~~ use of claim 30, wherein the condition is liver disease.

46. The ~~method~~ use of claim 45, wherein the liver disease is fatty liver disease or hepatitis.

47. The ~~method~~ use of claim 30, wherein the condition is an eye disorder.

48. The ~~method~~ use of claim 45, wherein the eye disorder is uveitis, macular degeneration, glaucoma, diabetic macular edema, blepharitis, diabetic retinopathy, a disease or disorder of the corneal endothelium, post-surgical inflammation, dry eye, allergic conjunctivitis, or a form of conjunctivitis.

49. The ~~method~~ use of claim 48, wherein the eye disorder is macular degeneration.

50. The ~~method~~ use of claim 49, wherein the macular degeneration is the dry form.

51. The ~~method~~ use of claim 49, wherein the macular degeneration is the wet form.

52. The ~~method~~ use of claim 48, wherein the disease or disorder of the corneal endothelium is Fuchs endothelial corneal dystrophy.

53. The ~~method~~ use of claim 30, wherein the condition is a lung disease.

54. The ~~method~~ use of claim 53, wherein the lung disease is pulmonary inflammation, pulmonary fibrosis, COPD, asthma, cystic fibrosis, or idiopathic pulmonary fibrosis.

55. The ~~method~~ use of claim 54, wherein the lung disease is pulmonary inflammation.

56. The ~~method~~ use of claim 54, wherein the lung disease is pulmonary fibrosis.

57. The ~~method~~ use of claim 54, wherein the lung disease is COPD.

58. The ~~method~~ use of claim 57, wherein the COPD is induced by cigarette smoke.

59. The ~~method~~ use of claim 54, wherein the lung disease is asthma.

60. The ~~method~~ use of claim 30, wherein the condition is sepsis.

61. The ~~method~~ use of claim 30, wherein the condition is mucositis resulting from radiation therapy or chemotherapy.

62. The ~~method~~ use of claim 61, wherein the mucositis presents orally.

63. The ~~method~~ use of claim 30, wherein the condition is associated with exposure to radiation.

64. The ~~method~~ use of claim 63, wherein the radiation exposure leads to dermatitis.

65. The ~~method~~ use according to any one of claims 63-64, wherein the radiation exposure is acute.

66. The ~~method~~ use according to any one of claims 63-64, wherein the radiation exposure is fractionated.

67. The ~~method~~ use according to any one of claims 27-66, wherein the pharmaceutical composition is to be administered in a single dose per day.

68. The ~~method~~ use according to any one of claims 27-66, wherein the pharmaceutical composition is to be administered in more than one dose per day.

69. The ~~method~~ use according to any one of claims 27-68, wherein the active ingredient is to be administered in a dose from about 1 mg/kg to about 2000 mg/kg.

70. The ~~method~~ use of claim 69, wherein the dose is from about 3 mg/kg to about 100 mg/kg.

71. The ~~method~~ use of claim 70, wherein the dose is about 3 mg/kg.

72. The ~~method~~ use of claim 70, wherein the dose is about 10 mg/kg.

73. The ~~method~~ use of claim 70, wherein the dose is about 30 mg/kg.

74. The ~~method~~ use of claim 70, wherein the dose is about 100 mg/kg.

75. The ~~method~~ use according to any one of claims 27-66, wherein the pharmaceutical composition is to be administered topically.

76. The ~~method~~ use of claim 75, wherein the topical administration is to be administered to the skin.

77. The ~~method~~ use of claim 75, wherein the topical administration is to be administered to the eye.

78. The ~~method~~ use according to any one of claims 27-66, wherein the pharmaceutical composition is to be administered orally.

79. The ~~method~~ use according to any one of claims 27-66, wherein the pharmaceutical composition is to be administered intraocularly.

80. The ~~method~~ use according to any one of claims 27-79, wherein the patient is a human.

81. The ~~method~~ use according to any one of claims 27-79, wherein the patient is a non-human animal.